title: GM-CSF- and IL-3-dependent CD34 expressing myeloid cell line (SAS-1) established from CD7 and CD34 expressing acute myeloblastic leukemic cells.
abstract: A novel factor-dependent human myeloid leukemia cell line (SAS-1) was established from a 69-year-old Japanese male suffering from CD7 and CD34 expressing acute myeloblastic leukemia (AML M2 in FAB classification). Morphological and cytochemical staining showed that SAS-1 cells were round with basophilic cytoplasm which is positive for peroxidase. Analysis of surface markers revealed that SAS-1 cells were myeloblasts derived from an immature progenitor origin, which express CD34. The consensus karyotype of the cell line was 41 XY 5q-, -7, 11p-, 12p+, -13, -14, -16, -17, -19, -22, with two markers. The proliferation of SAS-1 cells was dependent on the presence of either granulocyte-macrophage colony-stimulating factor (GM-CSF) or interleukin-3 (IL-3), and GM-CSF- and IL-3-induced proliferation was dose dependent. Neither, stem cell factor (SCF) nor granulocyte colony-stimulating factor (G-CSF) alone supported the growth of SAS-1 cells, but supported their viability for more than 4 days and arrested them in the G0/G1 phase. SCF also enhanced GM-CSF- or IL-3-induced growth, but other cytokines did not have this synergistic effect. Clonogenic assays revealed that SAS-1 cells formed 36.0 +/- 5.7 or 41.5 +/- 0.7 colonies/1000 cells in the presence of GM-CSF or IL-3, respectively. SCF also increased the number of colonies formed by GM-CSF or IL-3 treatment, while SAS-1 cells did not form colonies in the presence of SCF alone. SAS-1 cells may prove to be a useful tool for studying the regulation of the cell cycle, myeloid proliferation, and differentiation.
authors.affiliation: First Department of Internal Medicine, Kagawa Medical University, Japan.
authors.forename: K
authors.initials: K
authors.lastname: Sasaki
authors.forename: K
authors.initials: K
authors.lastname: Ikeda
authors.forename: K
authors.initials: K
authors.lastname: Kawakami
authors.forename: H
authors.initials: H
authors.lastname: Ohe
authors.forename: G
authors.initials: G
authors.lastname: Yamaoka
authors.forename: R
authors.initials: R
authors.lastname: Watanabe
authors.forename: H
authors.initials: H
authors.lastname: Ohnishi
authors.forename: K
authors.initials: K
authors.lastname: Kawanishi
authors.forename: J
authors.initials: J
authors.lastname: Takahara
authors.forename: S
authors.initials: S
authors.lastname: Irino
mesh_terms: D000368:Aged; D018952:Antigens, CD34 / Q000276:immunology*; D019011:Antigens, CD7 / Q000276:immunology*; D002455:Cell Division / Q000187:drug effects; D005819:Genetic Markers; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000494:pharmacology*; D006801:Humans; D007377:Interleukin-3 / Q000494:pharmacology*; D007621:Karyotyping; D015470:Leukemia, Myeloid, Acute / Q000235:genetics / Q000276:immunology / Q000473:pathology*; D008297:Male; D014407:Tumor Cells, Cultured
chemical_list: D018952:Antigens, CD34; D019011:Antigens, CD7; D005819:Genetic Markers; D007377:Interleukin-3; D016178:Granulocyte-Macrophage Colony-Stimulating Factor